Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis
Elisa Rojas‐Prats(Centro de Investigaciones Biológicas Margarita Salas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Loreto Martínez‐González(Consejo Superior de Investigaciones Científicas), Eva de Lago(Universidad Complutense de Madrid), Ángeles Martín‐Requero(Centro de Investigación Biomédica en Red), Carmen Gil(Instituto de Salud Carlos III), Nicole F. Liachko(University of Washington), Daniel I. Pérez(Cedars-Sinai Medical Center), Brian C. Kraemer(University of Washington), Claudia Gonzalo‐Consuegra(Universidad Complutense de Madrid)
Cited by 48
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293